|Awarded On||February 16, 2022|
|Title||Targeting immunosuppressive myeloid cells in tumor microenvironment|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Chengcheng Zhang|
|Cancer Sites||Breast, Ovary, Skin|
PD-1 and CTLA-4 immunotherapies have been successful in treating some types of cancers but not others. These therapies target molecules on one immune cell type - T cells - to activate dysfunctional T cells that are suppressed by tumors. Nevertheless, other types of immune cells, in particular myeloid cells, are present around the tumors in much larger numbers than T cells. The roles of these myeloid cells in cancer development are not well defined. A better understanding of the function of these myeloid cells in cancer immunology will support development of novel therapeutic strategies for cancer treatment.
We found that LILRB3, a protein present on the surface of human myeloid cells supp...